Research Summary

Dr. Cooperberg has a long experience in prostate cancer clinical and outcomes research, with specific areas of interest including early detection, risk assessment, biomarker validation, health services research, oncologic and health-related quality of life outcomes, comparative effectiveness, and disparities research. He has an extensive research history with CaPSURE and other registry and our institutional databases and tissue bank. He has a strong research interest in prostate cancer risk assessment, and led development and validation of the UCSF Cancer of the Prostate Risk Assessment (CAPRA) pre- and post-operative scores, as well as validation multiple tissue-based genomic markers now in wide clinical use.

From 2013 to 2020 he served as Associate Editor for European Urology, the leading peer-reviewed journal in urology, and as of 2023 am Associate Editor for the Journal of the National Cancer Institute. He also served as the physician lead on the American Urological Association’s new AUA Quality (AQUA) national disease registry with goals of documentation practice patterns, quality of care, and outcomes for patients across the nation with urologic diseases. In 2015, Cooperberg won the AUA Gold Cystoscope Award, awarded annually to one urologist based on contributions to the field within the first ten years of practice.

He has a longstanding interest in the development and validation of prostate cancer imaging tests and other biomarkers for prognostic risk, and led the pivotal validation studies for two of the three commercial tissue tests currently on the market for newly diagnosed prostate cancer. He has been PI on an R01 investigating miRNA as a noninvasive risk stratification tool for prostate cancer, and will soon start new one looking examining the black box of pathology artificial intelligence algorithms through the lens of spatial multi-omics. He serves as Urology co-Leader for the UCSF Helen Diller Family Comprehensive Cancer Center Prostate Program and is also Chief of Urology at the San Francisco VA Medical Center.

Research Funding

  • August 10, 2016 - July 31, 2021 - Improving Prostate Cancer Outcome Prediction Through Noninvasive exRNA Assessment , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA198145
  • August 8, 2012 - May 31, 2017 - Prospective validation of a multi-marker prostate cancer prediction model , Co-Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA160816

Education

Dartmouth College, Hanover, NH, BA, 1991-95, English
Yale University, New Haven, CT, MD, MPH, 1995-00, Medicine, Health Policy

Honors & Awards

  • 1995
    College honors: summa cum laude, Phi Beta Kappa, high honors in major, Presidential Scholar, Rufus Choate Scholar, B. William Hochman Prize in American Literature
  • 1996
    American Cancer Society Research Fellowship
  • 1999
    AMA John Conley Ethics Essay Contest, honorable mention
  • 2003
    UCSF Prostate Cancer Research Symposium, 2nd place, Clinical Research
  • 2004
    UCSF Prostate, Breast, Prostate SPORE Scientific Retreat, honorable mention, Clinical Research
  • 2005
    Northern California Urology Resident Research Symposium, 1st place, Clinical Research
  • 2006
    Northern California Urology Resident Research Symposium, 3rd place, Clinical Research
  • 2007
    AUA Gerald P. Murphy Prostate Scholar
  • 2007
    Northern California Urology Resident Research Symposium, 2nd place, Clinical Research
  • 2007
    Western Section AUA Miley B. Wesson Resident Essay Contest, 3rd place
  • 2008
    Society of Urologic Oncology Poster Session, 3rd place overall
  • 2008
    Western Section AUA Miley B. Wesson Resident Essay Contest, 3rd place
  • 2008
    Western Section AUA Poster Session I, 1st place
  • 2017
    2016 physician award, Marin Prostate Cancer Information and Support Group

Selected Publications

  1. Rojo Domingo M, Dornisch A, Conlin CC, Bagrodia A, Barrett T, Cooperberg M, Desloges JJ, Do DD, Do S, Hahn ME, Harisinghani M, Hollenberg G, Kallis K, Kane CJ, Kim J, Lee KL, Levine J, Liss MA, Liu J, Nakrour N, Osinski T, Pare C, Rakow-Penner R, Rupareliya R, Salmasi A, Simko J, Song Y, Sushentev N, Weinberg E, Woolen S, Dale AM, Shabaik AS, Seibert TM. Detection and Localization of Unfavorable-histology Prostate Cancer Using MRI and Whole-mount Histopathology. Eur Urol Oncol. 2026 Aug 07. View on PubMed
  2. Cooperberg MR, Shee K, Cowan JE, Ding CC, Todorovic T, Tenggara I, Tang S, Yamashita R, Royce T, Chen E, Tierney M, Ma X, Ren Y, Huang HC, Croucher DC, Simko JP, Feng FY, Showalter T, Carroll PR. Combining pathology artificial intelligence and genomic biomarkers to refine long-term postprostatectomy outcome prediction. J Natl Cancer Inst. 2026 Jul 10. View on PubMed
  3. Fanti S, Turco F, Tombal B, Walz J, Hofman MS, Hadaschik B, Emmett L, Tilki D, Pecoraro G, Salfi G, Attard G, Beltran H, Bjartell A, Briganti A, Burger IA, Castro E, Cerci JJ, Chiti A, Cooperberg M, Fizazi K, Fossati N, Gafita A, Gallina A, Goffin K, Horvath LG, Hugosson J, Iagaru A, James ND, Kasivisvanathan V, Koh DM, Kristiansen G, Kumar R, Lecouvet F, Loeb S, McKay RR, Morris MJ, Murphy DG, Murthy V, Naoun N, Oprea-Lager DE, Ost P, O'Sullivan J, Padhani AR, Palapattu G, Paone G, Petralia G, Roobol MJ, Sartor OA, Sathekge M, Schuster DM, Seibert TM, Spratt DE, Tempany C, Tunariu N, Vargas HA, Vogl UM, Wyatt AW, Zilli T, Lin HM, Omlin A, Gillessen S, Herrmann K. Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics. Eur Urol. 2026 Jul 03. View on PubMed
  4. Vickers AJ, Cooperberg M, Pavlovich CP, Carroll P, Eggener S. Prostate Cancer Mortality After Relabeling Low-Grade Prostate Cancer as Precancerous. JAMA Oncol. 2026 07 01; 12(7):767-771. View on PubMed
  5. Palsdottir T, Micoli C, Eklund M, Grönberg H, Jäderling F, Tilki D, Lin DW, Cooperberg MR, Eggener SE, Oeffinger KC, Nordström T, Vigneswaran HT. Stockholm3-Magnetic Resonance Imaging Population-Based Prostate Cancer Screening Study: Two-Year Follow-up. Ann Intern Med. 2026 Jul; 179(7):988-995. View on PubMed
  6. Cheng HH, Maxwell KN, Salari K, Cooperberg MR, Follmer K, Jeter JM, Jun G, Lee DJ, Patel HD, Schaeffer EM, Sokolova AO, Wolff EM, Lin DW. The 'Prostate Cancer Screening for People at Genetic Risk of Aggressive Disease' (PATROL) study. BJU Int. 2026 Jun 09. View on PubMed
  7. Tosoian JJ, Meyers JI, Moore B, Britton CJ, Chevli K, Rayford W, Gadzinski AJ, Joseph JV, Patel P, Kasraeian A, Sethi PS, Robinson HS, Assani KD, Rings V, Pierce J, Scarpato KR, Moses KA, Barocas DA, Chang SS, Penson DF, Sanda MG, Ross AE, Cooperberg MR, Salari K, Liss M, Zhang Y, Siddiqui J, Singhal U, Salami SS, Morgan TM, Palapattu GS, Wei JT, Cao J, Bala V, Oh Y, Heaton S, Zheng Y, Chinnaiyan AM. Noninvasive Urine Test Predicts Grade Group Upgrading in Patients on Active Surveillance for Prostate Cancer: Prospective Multisite Validation and Comparison with MRI. J Urol. 2026 May 20; 101097JU0000000000005095. View on PubMed
  8. Burwell A, Ithisuphalap J, Janes JL, Helms VM, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Klaassen Z, Terris MK, Rivera LG, Freedland SJ, Sleight AG. Marital status and post-radical prostatectomy outcomes: results from the SEARCH database. Support Care Cancer. 2026 May 19; 34(6). View on PubMed
  9. Song H, Xu J, Velazquez-Arcelay K, Demirci A, Raizenne BL, Hsu SC, Choi J, Pham JH, Chen YA, Weinstein HNW, Salzman I, Tsui M, Akutagawa J, Adingo W, Goldschmidt E, Carroll PR, Hong JC, Heaphy CM, Cooperberg MR, Greenland N, Campbell JD, Huang FW. Defining the combinatorial nature of gene modules in prostate cancer underlying lineage plasticity and metastasis. Res Sq. 2026 May 11. View on PubMed
  10. Do DD, Domingo MR, Conlin CC, Matthews I, Kallis K, Baxter MT, Ollison C, Song Y, Xu G, Zhong AY, Bagrodia A, Barrett T, Cooperberg M, Feng F, Hahn ME, Harisinghani M, Hollenberg GM, Javier-Desloges J, Kamran SC, Kane CJ, Kessler D, Kuperman J, Lee KL, Levine J, Liss MA, Margolis DJA, Murphy PM, Nakrour N, Ohliger MA, Osinski T, Pamatmat AJ, Pompa IR, Rakow-Penner R, Roberts JL, Santhosh K, Shabaik AS, Song D, Tempany CM, Trecarten S, Wehrli N, Weinberg EP, Woolen S, Dale AM, Seibert TM. Systematic effects of patient factors and scanner/protocol factors on a Restriction Spectrum Imaging (RSI) quantitative MRI biomarker for prostate cancer. Cancer Imaging. 2026 Apr 16; 26(1). View on PubMed
  11. Song H, Xu J, Velazquez-Arcelay K, Demirci A, Raizenne BL, Hsu SC, Choi J, Pham JH, Chen YA, Weinstein HNW, Salzman I, Tsui M, Akutagawa J, Adingo W, Goldschmidt E, Carroll PR, Hong JC, Heaphy CM, Cooperberg MR, Greenland N, Campbell JD, Huang FW. A single-cell and spatial atlas of prostate cancer reveals the combinatorial nature of gene modules underlying lineage plasticity and metastasis. bioRxiv. 2026 Mar 27. View on PubMed
  12. Chapin BF, Smaldone M, Zurita AJ, Wang J, Cooperberg MR, Gleave M, Delacroix SE, Davis J, Pettaway C, Pisters L, Adibi M, Chery L, Papadopoulos J, Ward J, Gregg J, Navai N, Corn P, Subudhi SK, Logothetis C, Kuban D, Nguyen Q, Tang C, Choi S, Hoffman K, Lozano M, Elsheftawi M, Achim M, Zhao Y, Ramesh N, Sei E, Navin N, Nogueras Gonzalez GM, Wang X, Zhu K, Troncoso P, Zhang M, McGuire S, Aparicio AM. A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy Versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer. Eur Urol. 2026 Mar 11. View on PubMed
  13. Cooperberg MR. AUA/SUO Guideline on Early Detection of Prostate Cancer (2026): Sound Science, Soft Power. J Urol. 2026 Jun; 215(6):661-663. View on PubMed
  14. Do DD, Conlin CC, Bagrodia A, Cooperberg M, Hahn ME, Harisinghani M, Hollenberg G, Javier-Desloges J, Kamran SC, Kane CJ, Lee KL, Liss MA, Margolis DJA, Murphy PM, Nakrour N, Ohliger MA, Osinski T, Rakow-Penner R, Domingo MR, Salmasi A, Shabaik AS, Song Y, Trecarten S, Wehrli N, Weinberg EP, Woolen S, Dale AM, Seibert TM. Post hoc estimation of a quantitative restriction spectrum imaging biomarker for prostate cancer detection using conventional MRI. J Appl Clin Med Phys. 2026 Mar; 27(3):e70543. View on PubMed
  15. Smani S, Sohoni N, Miszczyk M, Fazekas T, Rajwa P, Grimshaw AA, Sundaresan VM, Lokeshwar SD, Weinreb J, Sprenkle PC, Cooperberg MR, Seibert TM, Shariat SF, Catalona WJ, Leapman MS. Association between baseline prostate MRI PI-RADS classification and risk of Gleason upgrade during active surveillance: a systematic review and meta-analysis. World J Urol. 2026 Feb 15; 44(1):169. View on PubMed
  16. Shee K, Pace WA, Song JJ, Raizenne BL, Cowan JE, Wang L, Washington SL, Shinohara K, Nguyen HG, Carroll PR, Cooperberg MR. A High Decipher Genomic Risk Score Is Associated with Major Pathological Progression in Patients Undergoing Active Surveillance for Prostate Cancer. Eur Urol Oncol. 2026 Jan 30. View on PubMed
  17. Pace WA, Olshen A, Wang Y, Kenfield SA, Van Blarigan EL, Graff RE, Cowan J, Wang L, Tenggara I, Lopez K, Encabo K, Jones LW, Panchal N, Cooperberg MR, Carroll PR, Luke A, Pollak M, Chan JM. Inflammation and insulin profiles in men assigned to exercise vs. usual care for prostate cancer: results from the active surveillance exercise (ASX) randomized controlled trial. Cancer Causes Control. 2026 Jan 17; 37(2):22. View on PubMed
  18. Odisho AY, Liu AW, Pace WA, Carlisle MN, Krumm R, Cowan JE, Carroll PR, Cooperberg MR. Generative Artificial Intelligence Successfully Automates Data Extraction From Unstructured Magnetic Resonance Imaging Reports: Feasibility in Prostate Cancer Care. JCO Clin Cancer Inform. 2026 Jan; 10:e2400334. View on PubMed
  19. Carlisle MN, Pace WA, Liu AW, Krumm R, Cowan JE, Carroll PR, Cooperberg MR, Odisho AY. Development and Validation of a Generative Artificial Intelligence-Based Pipeline for Automated Clinical Data Extraction From Electronic Health Records: Technical Implementation Study. JMIR Bioinform Biotechnol. 2026 Jan 06; 7:e70708. View on PubMed
  20. Barata PC, Corrigan JK, La J, Culnan JM, Akama-Garren E, Dulberger KN, Dumontier C, Hansen J, Bihn JR, Bitting RL, Brophy MT, Cheng HH, Cooperberg MR, Do NV, Dorff T, Fojo AT, Gaziano JM, Goryachev SD, Halabi S, Hauger RL, Nanus DM, Rebbeck TR, Pan CX, Schoen MW, Swinnerton KN, Myrie K, Ramoni RB, Fillmore NR, Paller CJ, Rettig MB. Docetaxel Rechallenge vs Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer. JAMA Netw Open. 2026 Jan 02; 9(1):e2551231. View on PubMed

Go to UCSF Profiles, powered by CTSI